Important prognostic factors for survival in patients with malignant pleural effusion

BMC Pulmonary Medicine

Gilberto Perez Cardoso²  Edson Toscano Cunha¹  Rodrigo Baretta¹  Cyro Teixeira da Silva²  Mauro Musa Zamboni¹ 

[1] Pulmonology and Thoracic Surgery Division, Hospital do Câncer I, Instituto Nacional de Câncer/Ministério da Saúde, Rio de Janeiro, RJ, Brazil;Pulmonology Division, Hospital Antonio Pedro, Universidade Federal Fluminense, Niterói, RJ, Brazil

关键词: Survival;    Analysis;    Prognosis;    Malignant pleural effusion;    Neoplasm;   

Others  :  1170571
DOI  :  10.1186/s12890-015-0025-z

 received in 2014-09-18, accepted in 2015-03-17,  发布年份 2015

【 摘 要 】

Background

The approach to palliative treatment of malignant pleural effusion (MPE) should be individualized because these patients generally have poor survival. Our study aimed to develop a model to identify prognostic factors or survival time in patients diagnosed with MPE.

Methods

This is a retrospective, descriptive, observational study to identify prognostic factors related to MPE in patients with a confirmed cancer diagnosis. Cox regression analysis was used to determine significant potential prognostic factors with respect to survival time. Survival time was defined as the time from pathological diagnosis to death.

Results

One hundred and sixty-five patients were included; 77 were men (47%) and 88 were women (53%). The median age was 60 years, and all of the patients were pathologically proven to have MPE. Non-small-cell lung cancer (36.0%), breast carcinoma (26%), and lymphoma (13.0%) were the most frequently diagnosed tumors. The median overall survival of patients from the initial diagnosis was 5 months (range: 1.0–96.0 months). Kaplan–Meier univariate analysis showed that survival was significantly related to the following prognostic factors: ECOG PS (hazard ratio [HR] 10.0, 95% confidence interval [95% CI] 5.96 to 18.50, p < 0.0001), primary cancer site (HR 1.99, 95% CI 1.23 to 3.22, p < 0.01), positive pleural cytology (HR 1.25, 95% CI 0.88 to 1.78, p = 0.04), and positive histology (HR 1.33, 95% CI 0.97 to 1.81, p = 0.04). Other potential independent diagnostic factors that were examined did not affect survival. Cox regression analysis showed that only the ECOG PS was highly predictive of survival (HR 73.58, 95% CI 23.44 to 230.95, p < 0.0001).

Conclusions

ECOG PS is an independent predictor of survival in patients with MPE at initial diagnosis. This prognostic factor can help physicians select patients for appropriate palliative treatment of this syndrome.

【 授权许可】

   
2015 Zamboni et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Froudarakis ME: Pleural effusion in lung cancer: more questions than answers. Respiration 2012, 83(5):367-76.
• [2]Chernow B, Sahn SA: Carcinomatous involvement of the pleura. An analysis of 96 patients. Am J Med 1977, 63(5):695-702.
• [3]Haas AR, Sterman DH, Musani AI: Malignant pleural effusions - management options with consideration of coding, billing, and a decision approach. Chest 2007, 132(3):1036-41.
• [4]Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ: Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010. Thorax 2010, 65(Suppl 2):ii32-40.
• [5]Light RW: Pleural diseases. 6th edition. Lippincott Williams & Wilkins, Philadelphia; 2013.
• [6]Ernam D, Ataly F, Hasanogley HC, Kaplan O: Role of biochemical tests in the diagnosis of exudative pleural effusions. Clin Biochem 2005, 38(1):19-23.
• [7]Ekpe EE, Ikpe M, IN U: Palliative treatment of malignant pleural effusion. Diag Ther Stud 2013, 2(1):8-20.
• [8]Hooper C, Lee YC, Maskell N: Investigation of a unilateral pleural effusion in adults: British thoracic society pleural disease guideline 2010. Thorax 2010, 65(Suppl 2):ii4-17.
• [9]Martinez-Moragon E, Aparicio J, Sanchis J, Menéndez R, Rogado MC, Sanchis F: Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998, 65(2):108-13.
• [10]Teixeira LR, Pinto JAF, Marchi E: Malignant pleural effusion. J Bras Pneumol 2006, 32(Suppl 4):S182-9.
• [11]Zarogoulidis K, Zarogoulidis P, Darwiche K, Tsakiridis K, Machairiotis N, Kougioumtzi K, et al.: Malignant pleural effusion and algorithm management. J Thorac Dis 2013, 5(Suppl 4):S413-9.
• [12]Nam H-S: Malignant pleural effusion: medical approaches for diagnosis and management. Tuberc Respir Dis 2014, 76(5):211-7.
• [13]Michaud G, Berkowitz DM, Ernst A: Pleuroscopy for diagnosis and therapy for pleural effusions. Chest 2010, 138(5):1242-6.
• [14]Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.: Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 1982, 5(6):649-55.
• [15]Orr ST, Aisner J: Performance status assessment among oncology patients: a review. Cancer Treat Rep 1986, 70(12):1423-9.
• [16]Garber C: MedCalc software for statistics in medicine. Clin Chem 1998, 44(5):1370.
• [17]Altman DG, Royston P: What do we mean by validating a prognostic model? Statist Med 2000, 19(4):453-73.
• [18]Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53(282):457-81.
• [19]Harrell F, Lee KL, Califf RM, Pryor DB, Rosati RA: Regression modelling strategies for improved prognostic modelling. Stat Med 1984, 3(2):143-52.
• [20]Bustamante-Teixeira MT, Faerstein E, Latorre MR: Survival analysis techniques. Cad Saude Publica 2002, 18(3):579-94.
• [21]Mallet S, Royston P, Waters R, Dutton S, Altman DG: Reporting performance of prognostic models in cancer: a review. BMC Med 2010, 8:21-31. BioMed Central Full Text
• [22]Royston P, Altman DG: External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 2013, 13:33-9. BioMed Central Full Text
• [23]Burrows CM, Mathews C, Colt HG: Predicting survival in patients with recurrent symptomatic malignant pleural effusions. Chest 2000, 117(1):73-8.
• [24]Anevlavis S, Kouliatsis G, Sotiriou I, Koukourakis MI, Archontogeorgis K, Karpathiou G, et al.: Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration 2014, 87(4):311-6.
• [25]Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al.: Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014, 69:1098-104.
• [26]Bielsa S, Salud A, Martínez M, Esquerda A, Martín A, Rodríguez-Panadero F, et al.: Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Int Med 2008, 19:334-9.
• [27]Naito T, Satoh H, Ishikawa H, Yamashita YT, Kamma H, Takahashi H, et al.: Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 1997, 17(6):4743-6.
• [28]Ryu JS, Ryu HJ, Lee SN, Memon A, Lee SK, Nam HS, et al.: Prognostic impact of minimal pleural effusion in non-small cell lung cancer. J Clin Oncol 2014, 32(9):960-7.
• [29]Jimenez D, Diaz G, Gil D, Cicero A, Perez-Rodriguez E, Sueiro A, et al.: Etiology and prognostic significance of massive pleural effusions. Respir Med 2005, 99(9):1183-7.
• [30]Mountain CF: A new international staging system for lung cancer. Chest 1986, 89(4 Suppl):225S-33.
• [31]Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K: Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997, 3(1):47-50.
• [32]Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al.: The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2(8):706-14.
• [33]Porcel JM, Diaz JP, Chi DS: Clinical implications of pleural effusions in ovarian cancer. Respirology 2012, 17(7):1060-7.
• [34]Sears D, Hadju SI: The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol 1987, 31(2):85-97.
• [35]Winberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, et al.: Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. Ann Surg Oncol 2010, 17(6):1642-8.
• [36]von de Molengraft FJJM, Vooijs GP: Survival of patients with malignancy-associated effusions. Acta Cytol 1989, 33(6):911-6.
• [37]Heffner JE, Nieterr PJ, Barbieri C: Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000, 117(1):79-86.
• [38]Rodriguez-Panadero F, Lopez-Mejias J: Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies. Chest 1989, 95(2):320-4.
• [39]Huggins JT, Doelken P, Sahn SA: Intrapleural therapy. Respirology 2011, 16(6):891-9.
• [40]Davies HE, Mishra EK, Kahan BS, Wrightson JM, Stanton AE, Guhan A, et al.: Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving Dyspneia in patients with malignant pleural effusion. JAMA 2012, 307(22):2383-9.
• [41]Demmy TL, Gu L, Burkhalter JE, Toloza EM, D’Amico TA, Sutherland S, et al.: Optimal management of malignant pleural effusions (results of CALGB 3012). J Nat Comp Canc Netw 2012, 10:975-82.
• [42]Olden AM, Holloway R: Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? a cost-effectiveness analysis. J Palliat Med 2010, 13(1):59-65.
• [43]MacEachern P, Tremblay A: Pleural controversy: pleurodesis versus indwelling pleural catheters for malignant effusions. Respirology 2011, 16(5):747-54.
• [44]Estimativa de Câncer 2014 in http://www.inca.gov.br/estimativa2014/.